Daniel J Rader

List of Publications by Year in Descending Order

424 papers	56,737 citations	114 h-index	232 g-index
470 ext. papers	65,996 ext. citations	14.2 avg, IF	7.45 L-index

#	Paper	IF	Citations
424	Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization.. *Journal of Infectious Diseases*, **2022**,	7	8
423	Web of Science® Citation Median Metrics Overcome the Major Constraints of the Journal Impact Factor.. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2022**, ATVBAHA122317426	9.4	
422	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003501	5.2	2
421	Sortilin restricts secretion of apolipoprotein B-100 by hepatocytes under stressed but not basal conditions.. *Journal of Clinical Investigation*, **2022**,	15.9	2
420	Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease.. *Nature Genetics*, **2022**,	36.3	9
419	Whole genome sequencing reveals host factors underlying critical Covid-19.. *Nature*, **2022**,	50.4	8
418	The relationship between lipoproteins and insulin sensitivity in youth with obesity and abnormal glucose tolerance.. *Journal of Clinical Endocrinology and Metabolism*, **2022**,	5.6	2
417	Endothelial plasticity drives aberrant vascularization and impedes cardiac repair after myocardial infarction. **2022**, 1, 372-388		2
416	Impact of natural selection on global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2123000119	11.5	0
415	Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci.. *Frontiers in Genetics*, **2021**, 12, 787545	4.5	
414	MitoScape: A big-data, machine-learning platform for obtaining mitochondrial DNA from next-generation sequencing data. *PLoS Computational Biology*, **2021**, 17, e1009594	5	3
413	TRIB1 regulates LDL metabolism through CEBP□mediated effects on the LDL receptor in hepatocytes. *Journal of Clinical Investigation*, **2021**, 131,	15.9	2
412	Mendelian Randomization Analysis of Hemostatic Factors and Their Contribution to Peripheral Artery Disease-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 380-386	9.4	4
411	Disrupting upstream translation in mRNAs is associated with human disease. *Nature Communications*, **2021**, 12, 1515	17.4	5
410	Genome-first approach to rare EYA4 variants and cardio-auditory phenotypes in adults. *Human Genetics*, **2021**, 140, 957-967	6.3	4
409	A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease. *ELife*, **2021**, 10,	8.9	6
408	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell*, **2021**, 184, 1858-1864.e10	56.2	155

407	Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver. *Science Advances*, **2021**, 7,	14.3	1
406	ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 1753-1759	9.4	18
405	A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia. *Genetics in Medicine*, **2021**, 23, 1697-1704	8.1	2
404	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. *JCO Oncology Practice*, **2021**, 17, e1879-e1886	2.3	1
403	Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. *Frontiers in Immunology*, **2021**, 12, 650465	8.4	10
402	Association Between Genetic Variation in Blood Pressure and Increased Lifetime Risk of Peripheral Artery Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 2027-2034	9.4	7
401	Lipid droplet screen in human hepatocytes identifies TRRAP as a regulator of cellular triglyceride metabolism. *Clinical and Translational Science*, **2021**, 14, 1369-1379	4.9	1
400	A Genome-First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult Population. *Otolaryngology - Head and Neck Surgery*, **2021**, 1945998211029544	5.5	0
399	Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. *American Journal of Human Genetics*, **2021**, 108, 1350-1355	11	25
398	Sequencing of 640,000 exomes identifies variants associated with protection from obesity. *Science*, **2021**, 373,	33.3	22
397	Genetics of Postlingual Sensorineural Hearing Loss. *Laryngoscope*, **2021**, 131, 401-409	3.6	6
396	Polygenic Risk of Psychiatric Disorders Exhibits Cross-trait Associations in Electronic Health Record Data From European Ancestry Individuals. *Biological Psychiatry*, **2021**, 89, 236-245	7.9	8
395	HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition: SWAN-HDL Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 951-961	9.4	5
394	Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. *JNCI Cancer Spectrum*, **2021**, 5, pkaa120	4.6	8
393	Exome-wide evaluation of rare coding variants using electronic health records identifies new gene-phenotype associations. *Nature Medicine*, **2021**, 27, 66-72	50.5	11
392	Targeting the Coronavirus Nucleocapsid Protein through GSK-3 Inhibition **2021**,		1
391	Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank. *Journal of the American Medical Informatics Association: JAMIA*, **2021**, 28, 1178-1187	8.6	1
390	Impact of natural selection on global patterns of genetic variation, and association with clinical phenotypes, at genes involved in SARS-CoV-2 infection **2021**,		4

389	Health care worker seromonitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration. *JCI Insight*, **2021**, 6,	9.9	9
388	Associations of endogenous hormones with HDL novel metrics across the menopause transition: The SWAN HDL Study. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	2
387	Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease. *Circulation*, **2021**, 144, 353-364	16.7	6
386	Hepatic Manifestations of Mendelian Disorders of Cholesterol Biosynthesis and Cellular Metabolism.. *Clinical Liver Disease*, **2021**, 18, 266-273	2.2	
385	Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids. *Cell Metabolism*, **2021**, 33, 1592-1609.e7	24.6	5
384	LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	2
383	Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	14
382	Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins. *PLoS Genetics*, **2021**, 17, e1009802	6	1
381	Rare, Damaging DNA Variants in and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003399	5.2	2
380	Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study. *JAMA Network Open*, **2021**, 4, e2034461	10.4	11
379	Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia: A Quality Improvement Study. *Circulation: Cardiovascular Quality and Outcomes*, **2021**, 14, e007641	5.8	1
378	4365 Family-Based Study of Sleep in Autism Spectrum Disorder without Intellectual Disability. *Journal of Clinical and Translational Science*, **2020**, 4, 72-72	0.4	
377	EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression. *IScience*, **2020**, 23, 100973	6.1	4
376	Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nature Genetics*, **2020**, 52, 680-691	36.3	140
375	Systematically Sifting Big Data to Identify Novel Causal Genes for Human Traits. *Cell Metabolism*, **2020**, 31, 658-659	24.6	
374	Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients **2020**,		4
373	Genomic profiling of human vascular cells identifies TWIST1 as a causal gene for common vascular diseases. *PLoS Genetics*, **2020**, 16, e1008538	6	20
372	Annual Report on Sex in Preclinical Studies: Publications in 2018. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, e1-e9	9.4	4

371	Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program. *Circulation*, **2020**, 142, 1633-1646	16.7	24
370	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. *PLoS Medicine*, **2020**, 17, e1003288	11.6	15
369	Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors. *Cancer Genetics*, **2020**, 248-249, 49-56	2.3	
368	Teaching Old Drugs New Tricks: Statins for COVID-19?. *Cell Metabolism*, **2020**, 32, 145-147	24.6	22
367	SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Science Immunology*, **2020**, 5,	28	84
366	Heterozygous Gene Deficiency and Risk of Coronary Artery Disease. *Circulation Genomic and Precision Medicine*, **2020**, 13, 417-423	5.2	21
365	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. *PLoS ONE*, **2020**, 15, e0237430	3.7	5
364	Self-Organizing Human Induced Pluripotent Stem Cell Hepatocyte 3D Organoids Inform the Biology of the Pleiotropic Gene. *Hepatology Communications*, **2020**, 4, 1316-1331	6	5
363	, a Human Plasma Lipid GWAS Locus, Regulates Lipoprotein Metabolism in Mice. *Circulation Research*, **2020**, 127, 1347-1361	15.7	4
362	Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. *Journal of the American Heart Association*, **2020**, 9, e016507	6	8
361	LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase. *Circulation Research*, **2020**, 127, 1112-1114	15.7	27
360	A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. *Genetics in Medicine*, **2020**, 22, 102-111	8.1	21
359	Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function. *Brain*, **2020**, 143, 1114-1126	11.2	28
358	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study **2020**, 17, e1003288		
357	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study **2020**, 17, e1003288		
356	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study **2020**, 17, e1003288		
355	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study **2020**, 17, e1003288		
354	Genetics of height and risk of atrial fibrillation: A Mendelian randomization study **2020**, 17, e1003288		

353	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. *JAMA Oncology*, **2019**, 5, 514-522	13.4	23
352	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. *American Journal of Kidney Diseases*, **2019**, 73, 827-836	7.4	25
351	N-Glycosylation Defects in Humans Lower Low-Density Lipoprotein Cholesterol Through Increased Low-Density Lipoprotein Receptor Expression. *Circulation*, **2019**, 140, 280-292	16.7	18
350	Genetic and Epigenetic Fine Mapping of Complex Trait Associated Loci in the Human Liver. *American Journal of Human Genetics*, **2019**, 105, 89-107	11	20
349	Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. *Circulation*, **2019**, 140, 42-54	16.7	46
348	Soluble FMS-Like Tyrosine Kinase-1 Is a Circulating Biomarker Associated With Calcific Aortic Stenosis. *Journal of the American College of Cardiology*, **2019**, 73, 1364-1365	15.1	2
347	Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. *Nature Communications*, **2019**, 10, 1499	17.4	164
346	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. *Cardiovascular Research*, **2019**, 115, 204-212	9.9	25
345	Association of Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program. *Circulation*, **2019**, 140, 1031-1040	16.7	18
344	Genome-wide association study of peripheral artery disease in the Million Veteran Program. *Nature Medicine*, **2019**, 25, 1274-1279	50.5	73
343	Myeloid Tribbles 1 induces early atherosclerosis via enhanced foam cell expansion. *Science Advances*, **2019**, 5, eaax9183	14.3	14
342	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. *Nature Genetics*, **2019**, 51, 1574-1579	36.3	56
341	Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. *The Lancet Digital Health*, **2019**, 1, e393-e402	14.4	24
340	Manganese homeostasis: from rare single-gene disorders to complex phenotypes and diseases. *Journal of Clinical Investigation*, **2019**, 129, 5082-5085	15.9	8
339	A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity. *Journal of Proteome Research*, **2018**, 17, 2156-2164	5.6	15
338	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. *Journal of the American College of Cardiology*, **2018**, 71, 177-192	15.1	203
337	Autophagy Is Required for Sortilin-Mediated Degradation of Apolipoprotein B100. *Circulation Research*, **2018**, 122, 568-582	15.7	22
336	A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. *New England Journal of Medicine*, **2018**, 378, 1096-1106	59.2	350

335	Lipoprotein Disorders **2018**, 27-46		1
334	Mining the Stiffness-Sensitive Transcriptome in Human Vascular Smooth Muscle Cells Identifies Long Noncoding RNA Stiffness Regulators. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 164-173	9.4	32
333	Trials and Tribulations of CETP Inhibitors. *Circulation Research*, **2018**, 122, 106-112	15.7	132
332	Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. *Atherosclerosis*, **2018**, 268, 196-206	3.1	52
331	Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. *Journal of the American College of Cardiology*, **2018**, 72, 662-680	15.1	215
330	Directional ABCA1-mediated cholesterol efflux and apoB-lipoprotein secretion in the retinal pigment epithelium. *Journal of Lipid Research*, **2018**, 59, 1927-1939	6.3	12
329	Multi-ethnic genome-wide association study for atrial fibrillation. *Nature Genetics*, **2018**, 50, 1225-1233	36.3	277
328	Zinc transporter Slc39a8 is essential for cardiac ventricular compaction. *Journal of Clinical Investigation*, **2018**, 128, 826-833	15.9	27
327	Interrogation of the Atherosclerosis-Associated (Sortilin 1) Locus With Primary Human Hepatocytes, Induced Pluripotent Stem Cell-Hepatocytes, and Locus-Humanized Mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 76-82	9.4	23
326	2003 Mixed meal effects of neprilysin inhibition. *Journal of Clinical and Translational Science*, **2018**, 2, 44-44	0.4	78
325	Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002352	5.2	9
324	Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin. *Journal of the American Heart Association*, **2018**, 7, e03488	6	5
323	FP526VASCULAR CXCR4 LIMITS ATHEROSCLEROSIS BY MAINTAINING ARTERIAL INTEGRITY. *Nephrology Dialysis Transplantation*, **2018**, 33, i216-i216	4.3	1
322	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nature Genetics*, **2018**, 50, 1514-1523	36.3	260
321	Multiplexed Targeted Resequencing Identifies Coding and Regulatory Variation Underlying Phenotypic Extremes of High-Density Lipoprotein Cholesterol in Humans. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002070	5.2	5
320	Biomarkers of Calcific Aortic Valve Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 623-632	9.4	42
319	A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. *Journal of Lipid Research*, **2017**, 58, 752-762	6.3	17
318	Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport. *Journal of Lipid Research*, **2017**, 58, 731-741	6.3	10

317	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. *Journal of the American College of Cardiology*, **2017**, 69, 823-836	15.1	146
316	Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. *Nature*, **2017**, 544, 235-239	50.4	208
315	Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis. *Journal of Biological Chemistry*, **2017**, 292, 10444-10454	5.4	42
314	Loss of Cardioprotective Effects at the Locus as a Result of Gene-Smoking Interactions. *Circulation*, **2017**, 135, 2336-2353	16.7	36
313	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). *Circulation*, **2017**, 135, 2494-2504	16.7	126
312	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. *New England Journal of Medicine*, **2017**, 376, 1933-1942	59.2	406
311	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. *Cell Reports*, **2017**, 19, 1456-1466	10.6	24
310	Text mining applied to electronic cardiovascular procedure reports to identify patients with trileaflet aortic stenosis and coronary artery disease. *Journal of Biomedical Informatics*, **2017**, 72, 77-84	10.2	18
309	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. *Nature Genetics*, **2017**, 49, 1113-1119	36.3	184
308	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. *New England Journal of Medicine*, **2017**, 377, 211-221	59.2	416
307	Genetic-Variation-Driven Gene-Expression Changes Highlight Genes with Important Functions for Kidney Disease. *American Journal of Human Genetics*, **2017**, 100, 940-953	11	52
306	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. *Journal of the American College of Cardiology*, **2017**, 69, 2054-2063	15.1	226
305	A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. *Cell Stem Cell*, **2017**, 20, 478-489.e5	18	75
304	Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. *Cell Stem Cell*, **2017**, 20, 558-570.e10	18	102
303	Exome-wide association study of plasma lipids in >300,000 individuals. *Nature Genetics*, **2017**, 49, 1758-1766	36.3	310
302	Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport. *American Journal of Human Genetics*, **2017**, 101, 489-502	11	34
301	A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. *Nature Medicine*, **2017**, 23, 1086-1094	50.5	63
300	New insights into the role of glycosylation in lipoprotein metabolism. *Current Opinion in Lipidology*, **2017**, 28, 502-506	4.4	10

299	Can changes in the plasma lipidome help explain the cardiovascular benefits of the Mediterranean diet?. *American Journal of Clinical Nutrition*, **2017**, 106, 965-966	7	1
298	Polygenic determinants in extremes of high-density lipoprotein cholesterol. *Journal of Lipid Research*, **2017**, 58, 2162-2170	6.3	33
297	Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 1956-1962	9.4	25
296	Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing. *JAMA - Journal of the American Medical Association*, **2017**, 318, 381-382	27.4	100
295	Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. *Clinical and Translational Science*, **2017**, 10, 455-469	4.9	41
294	HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics. *Current Cardiology Reports*, **2017**, 19, 132	4.2	68
293	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. *Journal of Clinical Lipidology*, **2017**, 11, 1192-1200.e3	4.9	4
292	Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity. *Journal of Clinical Investigation*, **2017**, 127, 2407-2417	15.9	90
291	mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion. *Journal of Clinical Investigation*, **2017**, 127, 4207-4215	15.9	38
290	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. *Nature Genetics*, **2017**, 49, 1450-1457	36.3	136
289	Targeting ApoC-III to Reduce Coronary Disease Risk. *Current Atherosclerosis Reports*, **2016**, 18, 54	6	26
288	Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics. *Trends in Molecular Medicine*, **2016**, 22, 328-340	11.5	23
287	Recent advances in the pharmacological management of hypercholesterolaemia. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 436-46	18.1	23
286	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. *Science*, **2016**, 351, 1166-71	33.3	325
285	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. *Circulation: Cardiovascular Genetics*, **2016**, 9, 240-9		126
284	From Loci to Biology: Functional Genomics of Genome-Wide Association for Coronary Disease. *Circulation Research*, **2016**, 118, 586-606	15.7	36
283	New Therapeutic Approaches to the Treatment of Dyslipidemia. *Cell Metabolism*, **2016**, 23, 405-12	24.6	53
282	Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 994-1002	9.4	26

281	Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. *Journal of Clinical Investigation*, **2016**, 126, 1323-36	15.9	141
280	TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. *Nature*, **2016**, 535, 303-7	50.4	50
279	"Pheno"menal value for human health. *Science*, **2016**, 354, 1534-1536	33.3	6
278	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *Journal of the American College of Cardiology*, **2016**, 67, 2578-89	15.1	458
277	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. *Atherosclerosis*, **2016**, 250, 63-8	3.1	9
276	Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. *New England Journal of Medicine*, **2016**, 374, 1134-44	59.2	325
275	Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. *Journal of Clinical Lipidology*, **2016**, 10, 1137-1144.e3	4.9	20
274	Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. *Journal of Heart and Lung Transplantation*, **2016**, 35, 1295-1302	5.8	10
273	Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents. *Cell Metabolism*, **2016**, 24, 234-45	24.6	78
272	Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1880-8	9.4	51
271	Potent peroxisome proliferator-activated receptor-agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. *European Heart Journal*, **2015**, 36, 3020-2	9.5	24
270	Human genetics of atherothrombotic disease and its risk factors. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 741-7	9.4	7
269	A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nature Genetics*, **2015**, 47, 1121-1130	36.3	1290
268	A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 14623-8	11.5	76
267	Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. *American Journal of Cardiology*, **2015**, 115, 178-82	3	46
266	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. *Nature*, **2015**, 518, 102-6	50.4	463
265	Tribbles-1: a novel regulator of hepatic lipid metabolism in humans. *Biochemical Society Transactions*, **2015**, 43, 1079-84	5.1	15
264	HDL-cholesterol and cardiovascular disease: rethinking our approach. *Current Opinion in Cardiology*, **2015**, 30, 536-42	2.1	42

263	Lipoproteins **2015**, 1-14		
262	High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1515-9	9.4	63
261	Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, e3-9	9.4	49
260	Lipoprotein Physiology. *Contemporary Endocrinology*, **2015**, 1-12	0.3	2
259	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet, The*, **2015**, 386, 452-60	40	140
258	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 507-13	18.1	300
257	The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. *Circulation*, **2015**, 132, 2167-92	16.7	377
256	Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. *Journal of the American College of Cardiology*, **2015**, 66, 2201-2210	15.1	85
255	Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis. *Circulation Research*, **2015**, 116, 789-96	15.7	110
254	Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBP□*Journal of Clinical Investigation*, **2015**, 125, 3809-18	15.9	51
253	Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. *Journal of Clinical Investigation*, **2015**, 125, 3819-30	15.9	55
252	Generation of iPSCs as a Pooled Culture Using Magnetic Activated Cell Sorting of Newly Reprogrammed Cells. *PLoS ONE*, **2015**, 10, e0134995	3.7	22
251	Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *American Journal of Human Genetics*, **2014**, 94, 223-32	11	233
250	Future of cholesteryl ester transfer protein inhibitors. *Annual Review of Medicine*, **2014**, 65, 385-403	17.4	51
249	Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. *Stroke*, **2014**, 45, 24-36	6.7	245
248	Inactivating mutations in NPC1L1 and protection from coronary heart disease. *New England Journal of Medicine*, **2014**, 371, 2072-82	59.2	307
247	Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study. *European Heart Journal*, **2014**, 35, 2115-22	9.5	33
246	Genetics of lipid traits: Genome-wide approaches yield new biology and clues to causality in coronary artery disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 2010-2020	6.9	7

245	Dyslipidaemia: cardiovascular prevention--end of the road for niacin?. *Nature Reviews Endocrinology* , **2014**, 10, 646-7	15.2	9
244	HDL and cardiovascular disease. *Lancet, The*, **2014**, 384, 618-625	40	389
243	Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. *Circulation Research*, **2014**, 114, 1880-9	15.7	32
242	Lipidomic analyses of female mice lacking hepatic lipase and endothelial lipase indicate selective modulation of plasma lipid species. *Lipids*, **2014**, 49, 505-15	1.6	9
241	Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E841-7	5.6	50
240	A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production. *Atherosclerosis*, **2014**, 235, 470-6	3.1	10
239	AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia. *Circulation Research*, **2014**, 115, 591-9	15.7	29
238	Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. *Circulation*, **2014**, 129, 1022-32	16.7	181
237	Inhibition of endothelial lipase activity by sphingomyelin in the lipoproteins. *Lipids*, **2014**, 49, 987-96	1.6	11
236	Sortilin and lipoprotein metabolism: making sense out of complexity. *Current Opinion in Lipidology*, **2014**, 25, 350-7	4.4	59
235	Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 1057-63	9.4	55
234	Genetics of lipid traits and relationship to coronary artery disease. *Current Cardiology Reports*, **2013**, 15, 396	4.2	12
233	High-density lipoproteins: a consensus statement from the National Lipid Association. *Journal of Clinical Lipidology*, **2013**, 7, 484-525	4.9	215
232	Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. *European Journal of Heart Failure*, **2013**, 15, 1215-9	12.3	42
231	Discovery and refinement of loci associated with lipid levels. *Nature Genetics*, **2013**, 45, 1274-1283	36.3	1904
230	Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nature Genetics*, **2013**, 45, 1345-52	36.3	597
229	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. *Journal of the American College of Cardiology*, **2013**, 62, 1966-1976	15.1	91
228	Large-scale association analysis identifies new risk loci for coronary artery disease. *Nature Genetics*, **2013**, 45, 25-33	36.3	1172

227	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. *Lancet, The*, **2013**, 381, 40-6	40	480
226	The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. *Journal of the American College of Cardiology*, **2013**, 62, 1909-10	15.1	61
225	Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222. *Atherosclerosis*, **2013**, 227, 65-71	3.1	18
224	Lymphatics as a new active player in reverse cholesterol transport. *Cell Metabolism*, **2013**, 17, 627-8	24.6	6
223	Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 1788-94	9.4	32
222	Mighty minipig in fight against cardiovascular disease. *Science Translational Medicine*, **2013**, 5, 166fs1	17.5	13
221	Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2707-14	9.4	6
220	Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. *Human Gene Therapy Clinical Development*, **2013**, 24, 154-60	3.2	28
219	Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. *Human Gene Therapy*, **2013**, 24, 19-26	4.8	56
218	Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2909-14	9.4	76
217	Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 1706-13	9.4	113
216	Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. *Clinical Lipidology*, **2013**, 8, 635-648		10
215	Lipoprotein Disorders **2013**, 501-515		
214	Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet, The*, **2012**, 379, 1205-13	40	522
213	Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet, The*, **2012**, 380, 572-80	40	1523
212	ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. *Journal of Lipid Research*, **2012**, 53, 929-940	6.3	23
211	Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. *Cell Reports*, **2012**, 2, 1259-71	10.6	121
210	Prediabetic obese adolescents have a more atherogenic lipoprotein profile compared with normoglycemic obese peers. *Journal of Pediatrics*, **2012**, 161, 881-6	3.6	14

209	The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?. *Nature Medicine*, **2012**, 18, 1344-6	50.5	204
208	Secreted miRNAs suppress atherogenesis. *Nature Cell Biology*, **2012**, 14, 233-5	23.4	13
207	Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *American Journal of Human Genetics*, **2012**, 91, 823-38	11	189
206	Targeting high density lipoproteins in the prevention of cardiovascular disease?. *Current Cardiology Reports*, **2012**, 14, 684-91	4.2	24
205	Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. *Circulation*, **2012**, 125, 1905-19	16.7	614
204	Genomic medicine in the prevention and treatment of atherosclerotic cardiovascular disease. *Personalized Medicine*, **2012**, 9, 395-404	2.2	2
203	Sortilin as a regulator of lipoprotein metabolism. *Current Atherosclerosis Reports*, **2012**, 14, 211-8	6	35
202	Effect of interleukin 1 inhibition in cardiovascular disease. *Current Opinion in Lipidology*, **2012**, 23, 548-53	4.4	56
201	Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. *Science Translational Medicine*, **2012**, 4, 148ra115	17.5	90
200	Approach to the patient with extremely low HDL-cholesterol. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 3399-407	5.6	54
199	IL-1 and atherosclerosis: a murine twist to an evolving human story. *Journal of Clinical Investigation*, **2012**, 122, 27-30	15.9	33
198	Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. *Journal of Clinical Investigation*, **2012**, 122, 1677-87	15.9	77
197	Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. *Journal of Clinical Investigation*, **2012**, 122, 2807-16	15.9	151
196	Multi-ethnic analysis of lipid-associated loci: the NHLBI CARe project. *PLoS ONE*, **2012**, 7, e36473	3.7	39
195	Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. *Gastroenterology*, **2011**, 140, 1043-51	13.3	51
194	The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. *Journal of the American College of Cardiology*, **2011**, 58, 2068-75	15.1	95
193	Novel HDL-directed pharmacotherapeutic strategies. *Nature Reviews Cardiology*, **2011**, 8, 266-77	14.8	120
192	Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. *Lancet, The*, **2011**, 377, 383-92	40	399

191	Functional validation of new pathways in lipoprotein metabolism identified by human genetics. *Current Opinion in Lipidology*, **2011**, 22, 123-8	4.4	31
190	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nature Genetics*, **2011**, 43, 333-8	36.3	1394
189	PPAR□activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI. *Biochemical Pharmacology*, **2011**, 81, 934-41	6	16
188	Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. *New England Journal of Medicine*, **2011**, 364, 127-35	59.2	1403
187	Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1549-54	5.6	36
186	Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. *Journal of Lipid Research*, **2011**, 52, 361-73	6.3	122
185	Pharmacologic suppression of hepatic ATP-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. *Circulation*, **2011**, 124, 1382-90	16.7	54
184	Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol. *Circulation: Cardiovascular Genetics*, **2011**, 4, 145-55		66
183	Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol. *PLoS Genetics*, **2011**, 7, e1002393	6	28
182	Peroxisome proliferator-activated receptor-□activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 1276-82	9.4	42
181	Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. *PLoS Genetics*, **2011**, 7, e1001300	6	249
180	Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 320-7	9.4	22
179	Atherogenic Lipid Metabolism in Obesity **2011**, 293-309		1
178	From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. *Nature*, **2010**, 466, 714-9	50.4	820
177	Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*, **2010**, 466, 707-13	50.4	2742
176	Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. *Nature Genetics*, **2010**, 42, 692-7	36.3	155
175	Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. *PLoS ONE*, **2010**, 5, e13424	3.7	52
174	Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 781-6	9.4	92

173	Could exercise metabolomics pave the way for gymnomimetics?. *Science Translational Medicine*, **2010**, 2, 41ps35	17.5	9
172	Genetic variants influencing circulating lipid levels and risk of coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2264-76	9.4	318
171	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. *Journal of Clinical Investigation*, **2010**, 120, 2889-99	15.9	64
170	Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins. *Circulation Research*, **2010**, 107, 357-64	15.7	56
169	The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 796-801	9.4	309
168	Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. *Clinical Lipidology*, **2010**, 5, 793-809		9
167	Lipoprotein Disorders **2010**, 269-288		1
166	Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. *Circulation Journal*, **2010**, 74, 2263-70	2.9	83
165	Clinical Implications of Lipid Genetics for Cardiovascular Disease. *Current Cardiovascular Risk Reports*, **2010**, 4, 461-468	0.9	15
164	Future therapeutic directions in reverse cholesterol transport. *Current Atherosclerosis Reports*, **2010** , 12, 73-81	6	79
163	CXCL12: a new player in coronary disease identified through human genetics. *Trends in Cardiovascular Medicine*, **2010**, 20, 204-9	6.9	37
162	Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. *Biochemical Pharmacology*, **2010**, 80, 1450-7	6	42
161	Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels. *Clinical and Translational Science*, **2010**, 3, 140-6	4.9	13
160	Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. *Journal of Clinical Investigation*, **2010**, 120, 4410-4	15.9	108
159	Identification of the active form of endothelial lipase, a homodimer in a head-to-tail conformation. *Journal of Biological Chemistry*, **2009**, 284, 23322-30	5.4	34
158	Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. *Circulation*, **2009**, 120, 160-9	16.7	74
157	The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations. *European Heart Journal*, **2009**, 30, 1584-9	9.5	33
156	Fish oil promotes macrophage reverse cholesterol transport in mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 1502-8	9.4	41

155	Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 1496-501	9.4	45
154	Lecithin: cholesterol acyltransferase and atherosclerosis: another high-density lipoprotein story that doesnR quite follow the script. *Circulation*, **2009**, 120, 549-52	16.7	18
153	Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 140-6	9.4	37
152	Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics. *Trends in Cardiovascular Medicine*, **2009**, 19, 195-201	6.9	16
151	Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. *Clinical and Translational Science*, **2009**, 2, 127-33	4.9	60
150	Inflammation induces fibrinogen nitration in experimental human endotoxemia. *Free Radical Biology and Medicine*, **2009**, 47, 1140-6	7.8	25
149	Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nature Genetics*, **2009**, 41, 342-7	36.3	627
148	Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nature Genetics*, **2009**, 41, 334-41	36.3	884
147	Update on strategies to increase HDL quantity and function. *Nature Reviews Cardiology*, **2009**, 6, 455-63	14.8	151
146	The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. *Journal of Lipid Research*, **2009**, 50 Suppl, S189-94	6.3	415
145	Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. *Journal of Clinical Investigation*, **2009**, 119, 1042-50	15.9	144
144	Novel ENU-induced point mutation in scavenger receptor class B, member 1, results in liver specific loss of SCARB1 protein. *PLoS ONE*, **2009**, 4, e6521	3.7	12
143	Therapeutic Targeting of High-Density Lipoprotein Metabolism **2009**, 544-552		
142	Lipoprotein Disorders **2009**, 634-651		
141	Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. *American Journal of Cardiology*, **2008**, 102, 1438-43	3	120
140	The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. *Journal of the American College of Cardiology*, **2008**, 51, 1653-62	15.1	89
139	Laboratory assessment of HDL heterogeneity and function. *Clinical Chemistry*, **2008**, 54, 788-800	5.5	144
138	Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. *Journal of the American College of Cardiology*, **2008**, 51, 2199-211	15.1	205

137	Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2008**, 1781, 97-104	5	67
136	Translating molecular discoveries into new therapies for atherosclerosis. *Nature*, **2008**, 451, 904-13	50.4	367
135	Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells. *Atherosclerosis*, **2008**, 196, 201-209	3.1	12
134	Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?. *Cardiology Clinics*, **2008**, 26, 537-46	2.5	17
133	Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers. *Expert Review of Cardiovascular Therapy*, **2008**, 6, 1007-22	2.5	10
132	Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. *Journal of Lipid Research*, **2008**, 49, 1344-52	6.3	245
131	Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. *New England Journal of Medicine*, **2007**, 356, 148-56	59.2	438
130	Obesity and atherogenic dyslipidemia. *Gastroenterology*, **2007**, 132, 2181-90	13.3	95
129	CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. *Journal of the American College of Cardiology*, **2007**, 49, 442-9	15.1	121
128	Therapeutic Targeting of High-Density Lipoproteins **2007**, 507-522		
127	Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. *Cardiovascular Diabetology*, **2007**, 6, 15	8.7	58
126	Liver X receptor and farnesoid X receptor as therapeutic targets. *American Journal of Cardiology*, **2007**, 100, n15-9	3	45
125	Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. *Trends in Cardiovascular Medicine*, **2007**, 17, 35-43	6.9	18
124	Upregulation of macrophage endothelial lipase by toll-like receptors 4 and 3 modulates macrophage interleukin-10 and -12 production. *Circulation Research*, **2007**, 100, 1008-15	15.7	23
123	Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. *Circulation*, **2007**, 116, 1267-73	16.7	118
122	Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 2022-9	9.4	43
121	Glycosylation of endothelial lipase at asparagine-116 reduces activity and the hydrolysis of native lipoproteins in vitro and in vivo. *Journal of Lipid Research*, **2007**, 48, 1132-9	6.3	12
120	N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins. *Journal of Lipid Research*, **2007**, 48, 2047-57	6.3	20

119	Molecular regulation of macrophage reverse cholesterol transport. *Current Opinion in Cardiology*, **2007**, 22, 368-72	2.1	95
118	Lipases as modulators of atherosclerosis in murine models. *Current Drug Targets*, **2007**, 8, 1307-19	3	30
117	Mechanisms of disease: HDL metabolism as a target for novel therapies. *Nature Clinical Practice Cardiovascular Medicine*, **2007**, 4, 102-9		53
116	Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. *American Journal of Medicine*, **2007**, 120, S12-8	2.4	209
115	Hepatic proprotein convertases modulate HDL metabolism. *Cell Metabolism*, **2007**, 6, 129-36	24.6	98
114	Illuminating HDL--is it still a viable therapeutic target?. *New England Journal of Medicine*, **2007**, 357, 2180-3	59.2	107
113	A common variant on chromosome 9p21 affects the risk of myocardial infarction. *Science*, **2007**, 316, 1491-3	33.3	1322
112	Flaxseed reduces plasma cholesterol levels in hypercholesterolemic mouse models. *Journal of the American College of Nutrition*, **2007**, 26, 66-75	3.5	49
111	Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. *Journal of Clinical Investigation*, **2007**, 117, 2216-24	15.9	443
110	Genetic Disorders of Lipoprotein Metabolism **2007**, 23-35		1
109	Human genetics of variation in high-density lipoprotein cholesterol. *Current Atherosclerosis Reports*, **2006**, 8, 198-205	6	31
108	Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. *Circulation*, **2006**, 113, 2548-55	16.7	414
107	Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 182-8	9.4	142
106	High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. *Circulation Research*, **2006**, 98, 490-8	15.7	74
105	Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II. *Journal of Lipid Research*, **2006**, 47, 2191-7	6.3	16
104	Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. *Circulation*, **2006**, 113, 1140-50	16.7	82
103	Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. *Journal of Lipid Research*, **2006**, 47, 2297-305	6.3	69
102	Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 1852-7	9.4	48

101	Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. *Circulation*, **2006**, 113, 90-7	16.7	306
100	Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 1350-6	9.4	62
99	Substrate specificity of lipoprotein lipase and endothelial lipase: studies of lid chimeras. *Journal of Lipid Research*, **2006**, 47, 1803-11	6.3	40
98	Anti-Inflammatory and Antioxidant Functions of High Density Lipoproteins **2006**, 399-436		
97	Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 624-30	9.4	124
96	Persistent liver expression of murine apoA-I using vectors based on adeno-associated viral vectors serotypes 5 and 1. *Atherosclerosis*, **2006**, 186, 65-73	3.1	22
95	Molecular regulation of HDL metabolism and function: implications for novel therapies. *Journal of Clinical Investigation*, **2006**, 116, 3090-100	15.9	414
94	Apolipoprotein E and coronary disease: a puzzling paradox. *PLoS Medicine*, **2006**, 3, e258	11.6	18
93	A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. *Nature Genetics*, **2006**, 38, 68-74	36.3	304
92	Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. *PLoS Medicine*, **2006**, 3, e22	11.6	123
91	New insights into the regulation of HDL metabolism and reverse cholesterol transport. *Circulation Research*, **2005**, 96, 1221-32	15.7	787
90	Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell?. *Cell Metabolism*, **2005**, 1, 223-30	24.6	109
89	Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. *Current Opinion in Cardiology*, **2005**, 20, 301-6	2.1	26
88	Endothelial Lipase: A Novel Drug Target for HDL and Atherosclerosis? **2005**, 139-153		1
87	Current Drug Options for Raising HDL Cholesterol. *Current Treatment Options in Cardiovascular Medicine*, **2005**, 7, 15-23	2.1	6
86	Proprotein convertases [corrected] are responsible for proteolysis and inactivation of endothelial lipase. *Journal of Biological Chemistry*, **2005**, 280, 36551-9	5.4	81
85	Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 560-5	9.4	68
84	Gene therapy for lipoprotein disorders. *Expert Opinion on Biological Therapy*, **2005**, 5, 1029-38	5.4	7

83	Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1057-64	9.4	206
82	Novel approaches to the treatment of dyslipidemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 480-1	9.4	3
81	Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. *Journal of Lipid Research*, **2005**, 46, 2023-8	6.3	187
80	Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. *Circulation Research*, **2005**, 97, 763-71	15.7	149
79	Regulated expression of endothelial lipase by porcine brain capillary endothelial cells constituting the blood-brain barrier. *Journal of Neurochemistry*, **2005**, 94, 109-19	6	34
78	Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue. *Journal of Clinical Investigation*, **2005**, 115, 161-7	15.9	20
77	Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase□deficient mouse adipose tissue. *Journal of Clinical Investigation*, **2005**, 115, 161-167	15.9	38
76	Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. *Journal of Clinical Investigation*, **2005**, 115, 2870-4	15.9	245
75	Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *New England Journal of Medicine*, **2004**, 350, 1505-15	59.2	645
74	Role of N-linked glycosylation in the secretion and activity of endothelial lipase. *Journal of Lipid Research*, **2004**, 45, 2080-7	6.3	25
73	Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications. *Circulation*, **2004**, 110, 1338-40	16.7	24
72	Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. *Circulation Research*, **2004**, 94, 1554-61	15.7	60
71	Structural basis of endothelial lipase tropism for HDL. *FASEB Journal*, **2004**, 18, 1891-3	0.9	12
70	COX-2-derived prostacyclin confers atheroprotection on female mice. *Science*, **2004**, 306, 1954-7	33.3	356
69	NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *Journal of Biological Chemistry*, **2004**, 279, 48865-75	5.4	466
68	The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. *Nature Medicine*, **2004**, 10, 966-73	50.5	291
67	Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. *Trends in Cardiovascular Medicine*, **2004**, 14, 202-6	6.9	40
66	Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein. *Current Atherosclerosis Reports*, **2004**, 6, 398-405	6	29

65	The triglyceride-high-density lipoprotein axis: an important target of therapy?. *American Heart Journal*, **2004**, 148, 211-21	4.9	71
64	Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *New England Journal of Medicine*, **2004**, 350, 1495-504	59.2	3769
63	Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. *Journal of Clinical Investigation*, **2004**, 113, 609-18	15.9	32
62	Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. *Circulation Research*, **2003**, 92, 644-50	15.7	104
61	Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1914-20	9.4	78
60	Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. *Circulation*, **2003**, 108, 2121-6	16.7	121
59	Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway. *Journal of Biological Chemistry*, **2003**, 278, 34331-8	5.4	94
58	Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. *Circulation*, **2003**, 108, 661-3	16.7	358
57	Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. *American Journal of Physiology - Endocrinology and Metabolism*, **2003**, 285, E403-11	6	30
56	Therapy to reduce risk of coronary heart disease. *Clinical Cardiology*, **2003**, 26, 2-8	3.3	13
55	Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. *American Journal of Cardiology*, **2003**, 91, 18E-23E	3	83
54	Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. *American Journal of Cardiology*, **2003**, 91, 20C-23C; discussion 23C-24C	3	57
53	Regulation of reverse cholesterol transport and clinical implications. *American Journal of Cardiology* , **2003**, 92, 42J-49J	3	146
52	A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver. *Journal of Gene Medicine*, **2003**, 5, 567-75	3.5	20
51	Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. *Biochemistry*, **2003**, 42, 13778-85	3.2	34
50	Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation. *Cardiology Clinics*, **2003**, 21, 377-92	2.5	6
49	Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 2730-5	11.5	214
48	Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. *Molecular Pharmacology*, **2003**, 64, 249-58	4.3	45

47	Effects of nonlipolytic ligand function of endothelial lipase on high density lipoprotein metabolism in vivo. *Journal of Biological Chemistry*, **2003**, 278, 40688-93	5.4	49
46	The metabolic syndrome: more than the sum of its parts?. *Circulation*, **2003**, 108, 1546-51	16.7	361
45	High-density lipoproteins as an emerging therapeutic target for atherosclerosis. *JAMA - Journal of the American Medical Association*, **2003**, 290, 2322-4	27.4	47
44	Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2003**, 290, 765-72	27.4	152
43	Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 160-7	9.4	657
42	Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. *Journal of Clinical Investigation*, **2003**, 111, 357-62	15.9	172
41	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *Journal of Clinical Investigation*, **2003**, 111, 1795-803	15.9	160
40	Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. *Journal of Clinical Investigation*, **2003**, 111, 1795-1803	15.9	366
39	High-density lipoproteins and atherosclerosis. *American Journal of Cardiology*, **2002**, 90, 62i-70i	3	96
38	Normal production rate of apolipoprotein B in LDL receptor-deficient mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 989-94	9.4	40
37	Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 1213-8	9.4	103
36	Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. *Circulation*, **2002**, 106, 1321-6	16.7	121
35	Lipase H, a new member of the triglyceride lipase family synthesized by the intestine. *Genomics*, **2002**, 80, 268-73	4.3	37
34	Lipases and HDL metabolism. *Trends in Endocrinology and Metabolism*, **2002**, 13, 174-8	8.8	69
33	Characterization of the lipolytic activity of endothelial lipase. *Journal of Lipid Research*, **2002**, 43, 921-929	6.3	244
32	Characterization of the lipolytic activity of endothelial lipase. *Journal of Lipid Research*, **2002**, 43, 921-9	6.3	218
31	Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. *American Journal of Cardiology*, **2001**, 87, 476-9, A7	3	81
30	Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. *Circulation*, **2001**, 103, 2277-82	16.7	213

29	The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. *Journal of Clinical Investigation*, **2001**, 108, 1031-1040	15.9	228
28	Endothelial lipase: a new member of the triglyceride lipase gene family. *Current Opinion in Lipidology*, **2000**, 11, 141-7	4.4	77
27	Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. *Trends in Molecular Medicine*, **2000**, 6, 170-5		34
26	High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. *Current Atherosclerosis Reports*, **2000**, 2, 363-72	6	27
25	Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. *Molecular Therapy*, **2000**, 1, 189-94	11.7	36
24	Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 721-7	9.4	294
23	The endothelium and lipoproteins: insights from recent cell biology and animal studies. *Seminars in Thrombosis and Hemostasis*, **2000**, 26, 521-8	5.3	40
22	Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. *Journal of Biological Chemistry*, **2000**, 275, 10077-84	5.4	140
21	Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. *Molecular Therapy*, **2000**, 2, 256-61	11.7	56
20	Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 2162-70	9.4	97
19	Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. *Circulation*, **1999**, 100, 1816-22	16.7	317
18	A novel endothelial-derived lipase that modulates HDL metabolism. *Nature Genetics*, **1999**, 21, 424-8	36.3	424
17	Role of fibrates in the management of hypertriglyceridemia. *American Journal of Cardiology*, **1999**, 83, 30F-35F	3	34
16	ABC1: connecting yellow tonsils, neuropathy, and very low HDL. *Journal of Clinical Investigation*, **1999**, 104, 1015-7	15.9	63
15	Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. *Journal of Lipid Research*, **1999**, 40, 648-653	6.3	50
14	Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. *Journal of Lipid Research*, **1999**, 40, 2134-2139	6.3	123
13	Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. *Nature Medicine*, **1998**, 4, 1189-92	50.5	449
12	Lipoprotein(a) levels and heart transplantation atherosclerosis. *American Heart Journal*, **1998**, 136, 329-34	4.9	8

11	Increased formation of distinct F2 isoprostanes in hypercholesterolemia. *Circulation*, **1998**, 98, 2822-8	16.7	236
10	Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. *Current Opinion in Lipidology*, **1996**, 7, 117-23	4.4	48
9	Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 306-12	9.4	63
8	Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. *Annals of Internal Medicine*, **1994**, 120, 1012-25	8	155
7	Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. *Nature*, **1993**, 365, 65-9	50.4	423
6	Lipoprotein(a). *JAMA - Journal of the American Medical Association*, **1992**, 267, 1109	27.4	44
5	Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. *New England Journal of Medicine*, **1991**, 324, 1318-25	59.2	103
4	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations		1
3	A Mendelian randomization study of the role of lipoprotein subfractions in coronary artery disease		2
2	A trans-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation		5
1	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. *Nature Genetics*,	36.3	2